NYSE:BAX - Baxter International Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $91.33
  • Forecasted Upside: 11.06 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$82.24
▼ -1.85 (-2.20%)
1 month | 3 months | 12 months
Get New Baxter International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BAX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$91.33
▲ +11.06% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Baxter International in the last 3 months. The average price target is $91.33, with a high forecast of $100.00 and a low forecast of $85.00. The average price target represents a 11.06% upside from the last price of $82.24.

Buy

The current consensus among 13 contributing investment analysts is to buy stock in Baxter International. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/21/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/20/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/18/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 7 hold ratings
  • 0 sell ratings
9/16/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 7 hold ratings
  • 0 sell ratings
12/15/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/14/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2021BarclaysInitiated CoverageEqual Weight$93.00Low
i
4/30/2021CitigroupBoost Price Target$94.00 ➝ $98.00Low
i
4/30/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price TargetBuy$94.00 ➝ $98.00Low
i
4/29/2021Piper SandlerBoost Price TargetNeutral ➝ In-Line$80.00 ➝ $85.00Low
i
3/18/2021OppenheimerReiterated RatingBuyLow
i
2/5/2021Credit Suisse GroupLower Price TargetOutperform$99.00 ➝ $95.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
2/5/2021Raymond JamesLower Price TargetOutperform$88.00 ➝ $85.00Low
i
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$100.00 ➝ $80.00Low
i
1/6/2021UBS GroupDowngradeBuy ➝ Neutral$95.00 ➝ $85.00N/A
i
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$84.00 ➝ $90.00Low
i
12/15/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$96.00 ➝ $85.00Medium
i
11/2/2020Stifel NicolausLower Price TargetBuy$90.00 ➝ $88.00Low
i
10/30/2020Morgan StanleyLower Price TargetEqual Weight$90.00 ➝ $84.00Low
i
10/30/2020KeyCorpLower Price TargetOverweight$98.00 ➝ $94.00Low
i
10/12/2020Raymond JamesLower Price TargetOutperform$95.00 ➝ $88.00Low
i
10/9/2020UBS GroupLower Price TargetBuy$98.00 ➝ $96.00Medium
i
10/1/2020CitigroupUpgradeNeutral ➝ Buy$94.00Medium
i
9/4/2020ArgusDowngradeBuy ➝ HoldMedium
i
8/11/2020Credit Suisse GroupReiterated RatingBuy$99.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
7/31/2020Credit Suisse GroupReiterated RatingBuy$99.00High
i
Rating by Matt Miksic at Credit Suisse Group AG
7/31/2020Raymond JamesLower Price TargetOutperform$97.00 ➝ $95.00Medium
i
7/31/2020Morgan StanleyLower Price TargetEqual Weight$95.00 ➝ $90.00Low
i
7/30/2020OppenheimerReiterated RatingBuyLow
i
Rating by Suraj Kalia at Oppenheimer Holdings Inc.
6/23/2020OppenheimerInitiated CoverageOutperform$100.00Medium
i
5/1/2020UBS GroupBoost Price TargetBuy$95.00 ➝ $103.00Low
i
5/1/2020SVB LeerinkBoost Price TargetOutperform$96.00 ➝ $105.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
5/1/2020Credit Suisse GroupBoost Price TargetOutperform$97.00 ➝ $99.00Low
i
5/1/2020KeyCorpBoost Price TargetOverweight$92.00 ➝ $98.00Low
i
4/30/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $100.00Low
i
4/28/2020JPMorgan Chase & Co.Boost Price TargetOverweight$94.00 ➝ $96.00Low
i
4/20/2020Wells Fargo & CompanyBoost Price TargetOverweight$92.00 ➝ $104.00Low
i
4/14/2020BarclaysReiterated RatingHold$84.00High
i
4/13/2020Raymond JamesBoost Price TargetOutperform$90.00 ➝ $97.00Low
i
4/2/2020Wells Fargo & CompanyReiterated RatingBuyHigh
i
3/27/2020Morgan StanleyBoost Price TargetHold$88.00 ➝ $95.00Low
i
Rating by David Lewis at Morgan Stanley
3/19/2020Stifel NicolausUpgradeHold ➝ Buy$87.00 ➝ $95.00High
i
3/18/2020Wells Fargo & CompanyLower Price Target$102.00 ➝ $95.00High
i
3/18/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$109.00 ➝ $99.00High
i
Rating by Pito Chickering at Deutsche Bank Aktiengesellschaft
3/18/2020CitigroupLower Price TargetNeutral$94.00 ➝ $89.00High
i
3/18/2020Credit Suisse GroupLower Price TargetOutperform$98.00 ➝ $96.00High
i
3/18/2020Raymond JamesLower Price TargetNeutral ➝ Outperform$95.00 ➝ $90.00High
i
3/18/2020KeyCorpUpgradeSector Weight ➝ Overweight$92.00High
i
3/17/2020SVB LeerinkReiterated RatingOutperformHigh
i
Rating by D. Antalffy at SVB Leerink LLC
3/6/2020Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $98.00Medium
i
3/4/2020CitigroupInitiated CoverageNeutral$94.00High
i
2/14/2020Wells Fargo & CompanyBoost Price TargetOverweight$100.00 ➝ $102.00Low
i
2/12/2020The Goldman Sachs GroupInitiated CoverageBuy$104.00Low
i
2/6/2020CfraBoost Price TargetHold$87.00 ➝ $93.00Low
i
1/16/2020Wells Fargo & CompanyBoost Price TargetOverweight$95.00 ➝ $100.00Low
i
Rating by Larry Biegelsen at Wells Fargo & Company
1/13/2020UBS GroupReiterated RatingBuy$102.00High
i
1/2/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightHigh
i
Rating by David Lewis at Morgan Stanley
1/2/2020CitigroupUpgradeNeutral ➝ BuyHigh
i
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$80.00 ➝ $94.00High
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$89.00 ➝ $94.00Low
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
12/17/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$90.00 ➝ $88.00Medium
i
10/21/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$109.00High
i
Rating by Pito Chickering at Deutsche Bank Aktiengesellschaft
10/8/2019JPMorgan Chase & Co.Set Price TargetBuy$94.00Low
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
9/10/2019Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Matthew O'Brien at Piper Jaffray Companies
7/26/2019Royal Bank of CanadaSet Price TargetHold$87.00Low
i
Rating by Glenn Novarro at Royal Bank of Canada
7/26/2019BarclaysSet Price TargetHold$82.00Low
i
Rating by Kristen Stewart at Barclays PLC
7/26/2019Wells Fargo & CompanySet Price TargetBuy$95.00Low
i
Rating by Larry Biegelsen at Wells Fargo & Company
7/26/2019Raymond JamesBoost Price TargetOutperform$84.00 ➝ $95.00Low
i
7/26/2019Credit Suisse GroupBoost Price TargetReduce ➝ Outperform$84.00 ➝ $95.00Low
i
7/26/2019BMO Capital MarketsBoost Price TargetOutperform$95.00Low
i
7/25/2019Piper Jaffray CompaniesBoost Price TargetOverweight$90.00 ➝ $95.00Low
i
6/26/2019Wells Fargo & CompanyBoost Price TargetOutperform$89.00 ➝ $91.00Low
i
6/25/2019KeyCorpInitiated CoverageSector Weight ➝ Sector WeightMedium
i
6/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$80.00 ➝ $90.00Low
i
5/13/2019JPMorgan Chase & Co.Boost Price TargetOverweight$80.00 ➝ $88.00Low
i
4/22/2019CowenSet Price TargetHold$75.00Low
i
Rating by Josh Jennings at Cowen Inc
4/15/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$72.00 ➝ $75.00Low
i
Rating by Kristen Stewart at Barclays PLC
4/3/2019Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$80.00 ➝ $89.00Medium
i
3/5/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$80.00 ➝ $83.00Low
i
2/1/2019BarclaysUpgradeUnderweight ➝ Equal Weight$67.00 ➝ $72.00Low
i
2/1/2019Piper Jaffray CompaniesReiterated RatingOverweight$80.00Low
i
1/2/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$66.00 ➝ $77.00Low
i
1/2/2019CitigroupUpgradeNeutral ➝ Buy$69.00 ➝ $76.00Low
i
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$77.00Medium
i
12/4/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$72.00 ➝ $76.00High
i
11/27/2018UBS GroupInitiated CoverageBuy$80.00High
i
11/13/2018CitigroupLower Price TargetNeutral ➝ Neutral$76.00 ➝ $69.00Medium
i
11/8/2018Royal Bank of CanadaLower Price TargetPositive ➝ Sector Perform$76.00 ➝ $70.00N/A
i
11/5/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$75.00 ➝ $66.00Low
i
11/2/2018ArgusUpgradeHold ➝ Buy$70.00Low
i
11/1/2018Piper Jaffray CompaniesLower Price TargetOverweight$83.00 ➝ $72.00Low
i
11/1/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$86.00 ➝ $76.00Medium
i
11/1/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$90.00 ➝ $77.00Medium
i
11/1/2018Raymond JamesLower Price TargetOutperform ➝ Outperform$80.00 ➝ $74.00Low
i
11/1/2018Wells Fargo & CompanyLower Price TargetOutperform ➝ Outperform$82.00 ➝ $72.00Medium
i
10/15/2018BarclaysInitiated CoverageUnderweight ➝ Underweight$73.00Medium
i
10/11/2018Morgan StanleyBoost Price TargetUnderweight$68.00 ➝ $75.00Low
i
9/4/2018ArgusReiterated RatingHoldLow
i
7/31/2018CitigroupBoost Price TargetNeutral ➝ Neutral$74.00 ➝ $76.00Medium
i
7/27/2018Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$77.00 ➝ $83.00Medium
i
7/27/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$80.00 ➝ $85.00High
i
7/27/2018Royal Bank of CanadaReiterated RatingHold$76.00High
i
5/31/2018Piper Jaffray CompaniesReiterated RatingOverweight$77.00Medium
i
5/22/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$73.00 ➝ $83.00Low
i
5/17/2018Piper Jaffray CompaniesInitiated CoverageOverweight$77.00Low
i
4/30/2018CitigroupBoost Price TargetNeutral ➝ Neutral$70.00 ➝ $72.00Medium
i
4/30/2018Stifel NicolausBoost Price TargetHold ➝ Hold$71.00 ➝ $72.00Medium
i
2/20/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$80.00Low
i
2/6/2018CitigroupBoost Price TargetNeutral ➝ Neutral$66.00 ➝ $70.00Medium
i
2/2/2018Royal Bank of CanadaReiterated RatingHold$72.00Medium
i
2/2/2018BarclaysBoost Price TargetOverweight ➝ Overweight$73.00 ➝ $77.00Medium
i
2/2/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$74.00 ➝ $77.00Medium
i
1/3/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$73.00Medium
i
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$71.00Medium
i
1/2/2018Bank of AmericaUpgradeNeutral ➝ BuyHigh
i
1/2/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
i
11/22/2017Bank of AmericaReiterated RatingHoldN/A
i
11/22/2017Royal Bank of CanadaReiterated RatingHold$66.00N/A
i
10/26/2017Stifel NicolausReiterated RatingHold$65.00N/A
i
10/26/2017BarclaysBoost Price TargetOverweight$70.00 ➝ $73.00N/A
i
10/26/2017Morgan StanleyBoost Price TargetEqual Weight$59.00 ➝ $62.00N/A
i
10/15/2017CowenSet Price TargetHold$68.00N/A
i
Rating by Josh Jennings at Cowen Inc
10/13/2017CowenReiterated RatingHold ➝ NeutralN/A
i
10/13/2017BMO Capital MarketsReiterated RatingBuy$70.00N/A
i
10/3/2017Royal Bank of CanadaReiterated RatingHold$60.00Low
i
9/1/2017Royal Bank of CanadaReiterated RatingHold$60.00N/A
i
8/17/2017CitigroupInitiated CoverageNeutral ➝ Neutral$63.00Low
i
7/28/2017UBS GroupBoost Price TargetNeutral$57.00 ➝ $62.00Low
i
7/27/2017SVB LeerinkReiterated RatingOutperform$67.00 ➝ $75.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
7/27/2017CowenReiterated RatingMarket Perform$66.00 ➝ $68.00Low
i
7/27/2017BarclaysBoost Price TargetOverweight$64.00 ➝ $70.00Low
i
7/26/2017Cantor FitzgeraldSet Price TargetBuy$70.00Medium
i
Rating by Travis Steed at Cantor Fitzgerald
7/25/2017Morgan StanleyReiterated RatingUnderweight$52.00 ➝ $55.00Medium
i
7/11/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$55.00 ➝ $70.00Low
i
7/10/2017CowenReiterated RatingMarket Perform$57.00 ➝ $66.00Low
i
6/29/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$70.00Low
i
6/14/2017BarclaysBoost Price TargetOverweight$62.00 ➝ $64.00Low
i
5/31/2017Stifel NicolausBoost Price TargetHold$58.00 ➝ $61.00Low
i
5/16/2017The Goldman Sachs GroupReiterated RatingConviction-Buy$71.00High
i
5/1/2017CowenBoost Price TargetMarket Perform$48.00 ➝ $57.00Low
i
4/29/2017Evercore ISIReiterated RatingOutperform$57.00 ➝ $60.00Low
i
4/28/2017Morgan StanleyBoost Price TargetUnderweight$48.00 ➝ $52.00Low
i
4/27/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$55.00 ➝ $58.00Low
i
4/27/2017BMO Capital MarketsReiterated RatingHold$55.00Low
i
4/17/2017Evercore ISIReiterated RatingOutperform$57.00Low
i
4/4/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$54.00 ➝ $64.00Medium
i
Rating by D. Antalffy at SVB Leerink LLC
2/2/2017UBS GroupBoost Price TargetNeutral$51.00 ➝ $52.00N/A
i
2/2/2017BarclaysReiterated RatingOverweight$57.00 ➝ $60.00N/A
i
2/1/2017Evercore ISIBoost Price TargetBuy$50.00 ➝ $51.50N/A
i
10/26/2016Royal Bank of CanadaReiterated RatingSector Perform$50.00 ➝ $55.00N/A
i
10/26/2016Evercore ISIReiterated RatingBuy$52.00 ➝ $56.00N/A
i
Rating by Vijay Kumar at Evercore ISI
10/26/2016Royal Bank of CanadaBoost Price TargetSector Perform$50.00 ➝ $55.00N/A
i
10/13/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
9/15/2016BarclaysInitiated CoverageOverweight$52.00N/A
i
8/15/2016ArgusReiterated RatingHoldN/A
i
Rating by David Toung at Argus
7/28/2016UBS GroupBoost Price TargetNeutral$48.00 ➝ $50.00N/A
i
Rating by Matt Miksic at UBS Group AG
7/27/2016JPMorgan Chase & Co.Boost Price TargetNeutral$45.00 ➝ $48.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
7/27/2016Royal Bank of CanadaReiterated RatingHold$47.00 ➝ $50.00N/A
i
7/27/2016Royal Bank of CanadaBoost Price TargetSector Perform$47.00 ➝ $50.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
7/8/2016JPMorgan Chase & Co.Reiterated RatingHold$45.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
7/6/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
Rating by David Roman at The Goldman Sachs Group, Inc.
(Data available from 6/14/2016 forward)
Baxter International logo
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Read More

Today's Range

Now: $82.24
$82.12
$84.50

50 Day Range

MA: $84.43
$81.09
$88.01

52 Week Range

Now: $82.24
$74.79
$91.45

Volume

6,107,100 shs

Average Volume

2,679,397 shs

Market Capitalization

$41.35 billion

P/E Ratio

39.54

Dividend Yield

1.36%

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Baxter International?

The following Wall Street research analysts have issued research reports on Baxter International in the last year: Argus, Barclays PLC, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, KeyCorp, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Stifel Nicolaus, The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for BAX.

What is the current price target for Baxter International?

12 Wall Street analysts have set twelve-month price targets for Baxter International in the last year. Their average twelve-month price target is $91.33, suggesting a possible upside of 11.1%. Oppenheimer Holdings Inc. has the highest price target set, predicting BAX will reach $100.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $85.00 for Baxter International in the next year.
View the latest price targets for BAX.

What is the current consensus analyst rating for Baxter International?

Baxter International currently has 6 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BAX will outperform the market and that investors should add to their positions of Baxter International.
View the latest ratings for BAX.

What other companies compete with Baxter International?

How do I contact Baxter International's investor relations team?

Baxter International's physical mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier's listed phone number is 224-948-2000 and its investor relations email address is [email protected] The official website for Baxter International is www.baxter.com.